Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230019/S005

MediBeacon Transdermal GFR System

Medibeacon, Inc. · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONP230019/S005

What did the FDA approve?

The FDA record P230019/S005, dated 2026-10-02, documents an approval of a Special (Immediate Track) supplement to the MediBeacon Transdermal GFR System PMA, filed by Medibeacon, Inc. under product code SDK. The listed reason is a process change affecting a manufacturer, sterilizer, packager or supplier. Because the identifier shares the P230019 base number, the filing amends that existing PMA rather than covering a new device submission.

The stated change covers an additional package integrity test method for routine testing of Lumitrace and additional verification steps in the monitor manufacturing process. The record does not describe the test method, the verification steps, their acceptance criteria or any supporting data. The approval reflects the agency's acceptance of the described process changes; it is not reported evidence of safety, clinical effectiveness or a new indication for the device category, a transdermal test for assessment of glomerular filtration rate.

FDA approval order statement

approval for an additional package integrity test method for routine testing of Lumitrace, and additional verification steps in the monitor manufacturing process.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230019/S005
Regulatory pathway
PMA supplement
Product code
SDK
Decision code
APPR
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.

Product code
SDK
FDA device class
3

For the original device and its historical approval scope, see PMA P230019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230019 · Original PMA

    MediBeacon Transdermal GFR Measurement System (TGFR)

  2. P230019/S005 received

    Application receipt date recorded by FDA.

  3. P230019/S005 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230019

Product / regulatory recordCompanyPathwayDecision dateSource
Medibeacon, Inc.PMA approvalJan 17, 2025FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medibeacon, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records